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Allergen immunotherapy (AIT) is a guidelines-approved, disease-modifying treatment option for respiratory allergies,
including allergic rhinitis (AR) induced by pollen. The various AIT regimens employed to date in pollen-induced AR
can be classified as continuous (i.e. year-round) or discontinuous (i.e. pre-seasonal alone, co-seasonal alone or pre- and
co-seasonal). Pre-and co-seasonal regimens are typically used for sublingual allergen immunotherapy (SLIT) and have
economic and compliance advantages over perennial (year-round) regimens. However, these advantages must not come
at the expensive of poor efficacy or safety. The results of recent double-blind, placebo-controlled, randomized clinical trials
show that pre- and co-seasonal SLIT is safe and effective in patients with AR induced by grass pollen (treated with a tablet
formulation) or by birch pollen (treated with a liquid formulation). Progress in SLIT has been made in defining the optimal
dose of major allergen, the administration frequency (daily), the duration of pre-seasonal treatment (four months) and the
number of treatment seasons (at least three). Post-marketing, “real-life” trials of pre- and co-seasonal birch or grass pollen
SLIT regimens have confirmed the efficacy and safety observed in the clinical trials. In the treatment of pollen-induced AR,
pre- and co-seasonal SLIT regimens appear to be at least as effective and safe as perennial SLIT regimens, and are
associated with lower costs and good compliance. Good compliance may mean that pre- and co-seasonal SLIT
regimens are inherently more effective and safer than perennial SLIT regimens. When considering the pre- and
co-seasonal discontinuous regimen in particular, a 300 IR five-grass-pollen formulation is the only SLIT tablet with a
clinical development programme having provided evidence of short-term, sustained and post-treatment efficacy.
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immunoglobulin E (IgE)-mediated inflammatory disease
of the upper airways that affects up to 30% of adults and
up to 40% of children, and has an impact on asthma
[1-3]. Allergic conjunctivitis is a comorbidity in around
two-thirds of people with pollen-induced AR. It is now
accepted that AR has a considerable disease burden,
with a marked socioeconomic impact and negative ef-
fects on health-related quality of life, work and school
performance, sleep, mood and social functioning [4-10].
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unless otherwise stated.several weeks or several months each year is a major
atopic sensitizer in the general population in Europe and
North America [11,12]. Seasonal AR is associated with
well-defined pollen periods, the start date and duration
of which vary from year to year and as a function of the
geographic and climatic zone [13,14]. For example, the dur-
ation of Poaceae pollen seasons recorded at 13 European
pollen-monitoring stations varied from 69 days in Reykjavik
to 154 days in Thessaloniki [13]. Birch (Betula), olive (Olea
europaea) and cypress (Cupressus sp.) trees also produce
highly allergic pollens [14]. The duration of the Betulaceae
pollen season varies from 38 days in Reykjavik to 107 days
in Legnano (near Milan) [13]. Importantly, exposure to
pollen (and thus induction of clinical disease in atopic sub-
jects) is increasing as a result of climate change, with higher
pollen counts, longer pollen periods and less rainfall in
many regions [14-16].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Most cases of AR are treated with symptomatic, anti-
allergic medications (such as H1-antihistamines) and/or
anti-inflammatory medications (such as intranasal corti-
costeroids (ICSs)) [1,2,17,18]. However, around 30% of
patients (most of whom have moderate-severe AR) do
not gain sufficient disease control with symptomatic
medications [19]. AIT is a guidelines-approved, disease-
modifying treatment option for IgE-mediated respiratory
allergies [1,2,20-23]. The effect of AIT on symptoms is
at least as great as that produced by ICSs [24,25]. As a
disease-modifying treatment, AIT is clinically effective
for up to 12 years [26,27] and reduces the appearance of
new sensitizations and allergic asthma in patients with
AR [28]. Both subcutaneous immunotherapy (SCIT) and
sublingual immunotherapy (SLIT) are effective in AR,
according to the results of large-scale, double-blind,
placebo-controlled (DBPC) randomized clinical trials
(RCTs), position papers and meta-analyses [27,29-35].
Furthermore, SLIT preparations can be administered as
drop or tablet formulations [20,21,36-39]. Despite the
proven short-term and long-term efficacy of both SCIT
and SLIT and decades of clinical experience, there is still
little consensus on (i) the optimal dose of desensitizing
allergen (due to the low number of dose-ranging studies
for SLIT solutions), (ii) the administration frequency,
(iii) the overall treatment duration, (iv) the treatment
regimen, and (v) the seasonality of AIT in pollen-
induced AR [31,34].Administration regimens for the treatment of
pollen-induced AR
In AIT, multiyear administration regimens (Figure 1) can
be dichotomized as continuous (i.e. year-round) or discon-

















Figure 1 AIT regimens for seasonal allergic rhinitis.Setting aside the allergen build-up phase (during which
administration of the maintenance dose of allergen is
achieved over a number of weeks, days or even hours,
depending on whether conventional, rush or ultra-rush
protocols are applied), SCIT is generally administered via a
continuous, year-round maintenance regimen in which in-
jections performed in a medically supervised setting at
regular intervals (typically every 4 to 6 weeks for aeroaller-
gen extracts) for several years and thus over several pollen
periods (Figure 1) [22]). Injections with longer time inter-
vals have not been tested in DBPC RCTs. The literature
data suggest that the risk of a severe adverse reaction to
pollen SCIT is exacerbated during the corresponding peak
pollen period [40]. For example, Lockey et al.’s analysis of
data collected between 1945 and 1973 found that 41% of
the recorded SCIT-related deaths had occurred during the
pollen period [41]. Hence, the latest US practice parameter
for AIT confirms historical practice and suggests that main-
tenance dose levels may be reduced (and certainly not in-
creased) during periods when the patient is naturally
exposed to high levels of the disease-inducing allergen
[22,42,43] (Figure 1).
Despite the proven efficacy of SCIT, a number of safety
and ease-of-use concerns remain. Indeed, SLIT has advan-
tages in terms of safety and convenience (especially in chil-
dren) [20,21,44]. Although pre-seasonal-only, co-seasonal-
only and perennial regimens have all been evaluated for
SLIT formulations, a pre- and co-seasonal regimen is most
commonly used (Figure 1). A 2009 review of pollen SLIT
administration regimens (mostly involving drop formula-
tions) [45] listed three studies with a pre-seasonal-only
regimen (e.g. [46]), three with a co-seasonal-only regimen
(e.g. [47,48]), eight with a continuous or partially post-
seasonal regimen (e.g. [49]) and 27 with a pre- and co-
seasonal regimen. Historically, pollen SLIT drops have been
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istration is challenging because patients will not perceive
the benefit of SLIT after the pollen period has ended (i.e.
when their symptoms have disappeared). Longer periods of
medication are associated with poorer compliance and thus
a lower likelihood of effectiveness [50,51].
Conversely, pre- and co-seasonal regimens also have
limitations. Trials of a five-grass pollen SLIT tablet for-
mulation have shown that 2 months of pre-seasonal
treatment (followed by co-seasonal treatment) is less ef-
fective than 4 months of pre-seasonal treatment [52,53].
Similarly, a trial of a single-grass pollen SLIT tablet
formulation found that the magnitude of the reductions
in rhinoconjunctivitis symptom and medication scores
increased with the duration of preseasonal treatment
(4 months appeared to be optimal) [54]. Hence, a patient
with a pollen allergy following a pre- and co-seasonal
regimen from one year to another must remember to
obtain medication and initiate treatment long enough
ahead of the pollen season. This particular problem (per-
sistence of treatment) is avoided if a year-round regimen
is strictly adhered to. In a study in Germany, the prescrip-
tion renewal rate (a proxy for treatment persistence) for
SLIT or subcutaneous immunotherapy formulations were
higher (at 55%–71%) than those reported elsewhere for
conventional medications [55].
A large body of evidence attests to the safety and effi-
cacy of pre- and co-seasonal regimens for pollen SLIT
drops when administered for one season or several con-
secutive seasons. Recently, Worm et al. performed a ro-
bust, two-season, DBPC RCT of pre- and co-seasonal
treatment with a 300 index of reactivity (IR) birch pollen
sublingual solution in 574 adult immunotherapy-naïve
patients with birch-pollen-induced allergic rhinocon-
junctivitis at 56 investigating centres in 11 European
countries [56]. The treatment started 4 months before
the expected pollen period. At the start of the study,
68% of the patients were polysensitized, 20% had mild-
to-moderate asthma and 54% had oral allergy syndrome.
The primary efficacy endpoint over the second birch
pollen period) was found to be significantly lower (p <
0.0001) in the active SLIT group (relative difference vs.
placebo: 30.6%; difference in the least-squares (LS)
means: −2.04 [95% confidence interval: −2.69; −1.40]). A
19.0% difference was also seen for active SLIT in the first
pollen period. The average medication score was signifi-
cantly lower in the 300 IR SLIT group in both seasons,
with relative LS mean differences of −29.3% and −41.9%,
respectively (p < 0.0001 for both). Active treatment was
associated with a better Rhinoconjunctivitis Quality of
Life Questionnaire (RQLQ) score in the first and second
pollen periods, with relative LS mean differences of −23.1%
and −34.5%, respectively. Treatment-emergent adverse
events (TEAEs) were no more frequent in the 300 IR SLITgroup than in the placebo group and were less frequent in
the second season (respectively 70.7% and 64.0% of patients
affected in season 1, and 46.8% and 48.6% p in season 2.
This decrease over time was also observed for common,
local adverse events (AEs) such as oral pruritus (24.7% of
patients affected in season 1 and 8.3% affected in season 2
in the SLIT group; 3.8% and 0.8% in the placebo group,
respectively. The treatment’s efficacy and the frequency of
TEAEs did not appear to depend on the presence or ab-
sence of oral allergy syndrome [56].
In a multicentre, DBPC, randomized phase III trial,
Wahn et al. [57] randomized 207 children aged between
4 and 12 with grass pollen AR/rhinoconjunctivitis with
or without bronchial asthma into an active treatment
group (SLIT with an aqueous six-grass pollen extract)
and a placebo group. A pre- and co-seasonal regimen
was applied. The primary efficacy end point was the
comparison of the change of the area under the curve
for the symptom–medication score, starting from the
baseline season to the first grass pollen season after the
initiation of treatment. The values were -212.5 and -97.8
in the active SLIT group and the placebo groups, re-
spectively (p < 0.004), evidencing a significantly greater
reduction in severity in the active SLIT group. In terms
of safety, 75.9% of the patients in the active SLIT treat-
ment group experienced at least one AE (compared with
32.7% of the patients in the placebo group) but no
treatment-related severe AEs were recorded. However,
only one pollen period was studied; the effect of treat-
ment discontinuation and resumption could not there-
fore be assessed.
Although most studies of pre- and co-seasonal SLIT
regimens have dealt with grass and birch pollen formula-
tions, other pollens have been studied. For example, pre-
and co-seasonal SLIT with a standardized aqueous rag-
weed pollen extract was studied by Creticos et al. [58] A
total of 429 patients were randomized (active SLIT: n =
218; placebo: n = 211) into a multicentre, DBPC, ran-
domized, phase III trial in North America. The treat-
ments were administered between April 2011 (i.e. at
least 4 months before the start of the ragweed pollen
period in October) and November 2011 (the end of the
period). The primary efficacy end point was the average
daily rhinoconjunctivitis symptom-medication score over
the course of the ragweed pollen season; the value in the
SLIT group (0.82 ± 1.64) was significantly lower than in
the 1.44 ± 2.40 in the placebo group (p < 0.001). Again,
only one pollen period was studied and the effect of treat-
ment discontinuation and resumption was not assessed.
Although DBPC RCTs remain the gold standard for
evaluating investigational products, “real-life” studies are
essential for completing effectiveness and safety under
“real-life” conditions in the target patient population. To
this end, Hadler et al. performed an open, prospective,
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IR birch pollen SLIT solution in 716 polyallergic and
monoallergic patients (mean ± SD age: 38 ± 16; age range
3-87) over two pollen seasons [59]. A pre- and co-
seasonal regimen was applied. The patients’ symptoms
were scored on a hybrid scale that took account of dis-
ease severity and frequency for rhinitis alone, conjunc-
tivitis alone and rhinoconjunctivitis. The mean rhinitis
score in the birch season prior to the study was 4.83.
This value fell to 3.17 in the first pollen season and 2.31
(a 52% reduction, p < 0.001) in the second pollen season.
The mean conjunctivitis score fell from 3.74 to 2.1 and
then 1.69 (a 55% reduction, p < 0.001). Lastly, the mean
rhinoconjunctivitis score fell from 3.76 to 2.29 and then
1.76 (a 53% reduction, p < 0.001). In a subgroup analysis,
the 300 IR pollen SLIT solution appeared to be similarly
effective in mono-allergic and polyallergic patients and
in those with an intra-seasonal start to treatment. The
percentage of patients requiring symptomatic medica-
tion was also significantly lower (p < 0.001) during the
first and second pollen season (59% and 48%, respect-
ively, compared with 81% before the study. Both mono-
allergic and poly-allergic patients gained clinical relief.
The 300 IR birch pollen SLIT solution was well toler-
ated, and 97% of the patients evaluated tolerability as
“good” or “very good”. Ninety percent of the patients did
not report an adverse event during the two treatment
seasons [59]. In clinical practice, the majority of patients re-
ceiving sublingual immunotherapy with allergen-specific
300 IR SLIT solution are satisfied with treatment [60], and
compliance and prescription renewal rates are relatively
high [55,61].
Taken as a whole, these “real-life” findings for 300 IR
birch pollen SLIT solution confirmed the results of the
DBPC RCTs.
The third main type of AIT formulation is the SLIT
tablet. Two tablet formulations of grass pollen SLIT (a
single-grass tablet [36,37] and a five-grass pollen tablet
[38,39]) have been approved to date for an indication of
grass-pollen-induced AR (with or without conjunctivitis)
in adults and children. According to the respective
summaries of product characteristics and the pivotal
DBPC RCTs, a 75,000 standardized quality tablet (SQ-T)
single-grass SLIT tablet [36,37] is approved for adminis-
tration with a continuous, year-round regimen (starting
before the first pollen season; Figure 1), whereas a 300
IR five-grass SLIT tablet [38,39] is approved for adminis-
tration with a discontinuous pre-and co-seasonal regi-
men (i.e. starting four months before the expected
start of the pollen season and finishing at the end of
the pollen season; Figure 1). Hence, the total treat-
ment duration per year is between 5 and 7 months
(depending on the duration of the pollen season) and
the onset of action (in an allergen challenge chamberstudy) was found to occur after one month of treat-
ment [62].
Over the last 10 years, the safety and/or efficacy of
pre-seasonal and co-seasonal treatment with a novel,
300 IR five-grass-pollen SLIT tablet has been unambigu-
ously demonstrated in a series of pre- and post-marketing
clinical trials in adult and paediatric populations [39].
Worldwide, a total of 2,512 study participants have been
randomized to receive either the five-grass-pollen SLIT tab-
let (n = 1,514) or a placebo (n = 998) [39]. Furthermore, the
300 IR five-grass-pollen SLIT tablet was proven to be simi-
larly effective in several clinical profiles (monosensitized pa-
tients, polysensitized patients, patients with high symptom
scores and patients with high skin sensitivity) [63]. After
the pivotal, single-season Phase II/III DBPC RCT in which
the dose of 300 IR was selected for further investigation
and registration [64], the 300 IR five-grass-pollen SLIT tab-
let’s sustained efficacy and efficacy after discontinuation of
treatment was investigated by Didier et al. in a 5-year
DBPC RCT in adults with AR at centres in the European
Union and Canada [39,52,53]. In fact, the European Medi-
cines Agency currently requires AIT preparations to have
(i) efficacy in the first season after the start of treat-
ment, (ii) a proven, sustained clinical effect (defined as
the maintenance of significant and clinically relevant
efficacy during two to three treatment years) and (iii)
long-term efficacy (defined as sustained significant and
clinically relevant efficacy in post-treatment years, i.e.
a disease-modifying effect) [65].
Hence, Didier et al. investigated three seasons of pre-
seasonal and co-seasonal treatment with a 300 IR five-
grass-pollen SLIT tablet in adult patients (aged 18 to 50)
with a history of seasonal AR to grass pollen for more than
two pollen seasons and continued to monitor the patients
for a further two treatment-free seasons [39,52,53,66]. A
total of 633 patients were randomized into one of three
groups: (i) 300 IR grass pollen SLIT tablet, with active treat-
ment starting 4 months (the 4 M group) before the ex-
pected start of the pollen season followed by co-seasonal
treatment; (ii) 300 IR grass pollen SLIT tablet, with first a
placebo taken for 2 months (starting 4 months before the
expected start of the pollen season, to maintain the blind-
ing), followed by 2 months of active treatment (the 2 M
group) and then co-seasonal active treatment, and lastly
(iii) placebo treatment starting 4 months before the ex-
pected start of the pollen season, followed by co-seasonal
treatment. These discontinuous treatments were adminis-
tered for three pollen seasons (years 1 to 3). After the end
of the third treatment season, patients were monitored over
the following two treatment-free pollen season (years
4 and 5). Of the 633 randomized patients, 457 com-
pleted year 3 and 435 contributed to the (post-treatment)
efficacy analyses in year 4. The study’s primary efficacy end-
point was a symptom score over the third pollen period.
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junctivitis symptom scores (sneezing, rhinorrhoea, nasal
pruritus, nasal congestion, ocular pruritus and watery eyes),
the average medication score and the RQLQ score. In year
4, the symptom scores in the two active treatment groups
were similarly and significantly lower than in the placebo
group, and significant efficacy was determined in year 5
[66]. In a subsequent post hoc analysis, the mean LS daily
combined score was found to be 28.1% lower in the 300 IR
tablet group than the placebo group p = 0.0478), thus dem-
onstrating long-term efficacy and a disease-modifying effect
of the 300 IR five-grass-pollen SLIT tablet. The difference
in LS means between the 4 M group and the 2 M group
was not statistically significant. The 300 IR five-grass-pollen
SLIT tablet’s safety profile over the entire study period was
consistent with previous reports, with generally mild, tran-
sient, local AEs [39,52,53,67]. Over the first three treatment
seasons, the incidence and severity of TEAEs decreased
from one year to the next in all three treatment groups. In
the first treatment season, the most frequently reported
TEAEs were oral pruritus (30% and 11.4% in the active and
placebo groups, respectively), throat irritation (15% and
3.7%, respectively), and mouth oedema (6% and 1.4%, re-
spectively). During the first treatment year (but not the
second and the third treatment year), the number of dis-
continuations due to TEAEs was higher in patients treated
with the 300 IR formulation (7.2% in the two active groups
and 1.4% in the placebo group). During the fourth year of
study, the incidence of treatment-emergent AEs was
similar in the 300 IR (4 M), 300 IR (2 M) and placebo
groups, with values of 31.7%, 34.8% and 35.9%, re-
spectively. Importantly, exacerbation of asthma was
not an issue, and the one case in the 300 IR (4 M) and
the two cases in the placebo group were not judged to
be related to the study treatment [52,53].
Following on from the above-mentioned DBPC RCTs,
a number of post-marketing studies in Europe have con-
firmed the 300 IR five-grass-pollen SLIT tablet’s safety
and/or efficacy when a pre- and co-seasonal regimen is
used in actual clinical practice. In Germany, the OPTIMAL
multicentre, prospective, open-label, non-interventional
study assessed the tolerability and effectiveness of two con-
secutive years of a pre- and co-seasonal treatment regimen
with the 300 IR five-grass-pollen SLIT tablet in a total of
1,482 adult and paediatric patients (including 248 children
aged from 4 to 11 and 201 adolescents aged from 12 to 17)
[68]. Compared with the baseline season, the mean
rhinoconjunctivitis scores were significantly lower in
the two treatment seasons (by 51% and 64%, respect-
ively; p < 0.001). Importantly, the asthma symptom
score for the 522 patients with comorbid mild asthma
was also significantly lower in the two treatment sea-
sons (by 60% and 70%, respectively for year 1 and 2,
respectively; p < 0.001). When considering the childrenalone, the mean rhinoconjunctivitis score fell from 4.1
in the baseline season to 1.93 after the first season and
1.39 after the second. For the adolescent subgroup,
the corresponding values were 4.05, 1.97 and 1.39. The
mean rhinoconjunctivitis score fell in both mono-allergic
and polyallergic subjects, confirming the DBPC RCT re-
sults. For example, the respective baseline, year 1 and year
2 rhinoconjunctivitis score were 4.05, 1.95 and 1.29 in
mono-allergic children and 4.09, 1.94 and 1.46 in polyaller-
gic children [68].
A similar multicentre, open-label, observational, cross-
sectional, single-season study of pre- and co-seasonal
treatment with a 300 IR five-grass-pollen SLIT tablet
has been carried out in Spain [69]. A total of 226 adult
patients (mean age: 33.9 ± 11.5) were included in the
study. Fifty-five percent had mild asthma and 92% of pa-
tients had persistent moderate-severe AR (according to
the Allergic Rhinitis and its Impact on Asthma criteria
[1,2]). Following pre- and co-seasonal treatment with
the 300 IR five-grass-pollen SLIT tablet, the percentage
of patients with moderate-severe AR was 30%. Symptom-
atic medication use also fell; the percentages of patients
using oral H1-antihistamines and ICSs decreased from 92%
and 77%, respectively, at baseline to 62% and 28%, respect-
ively, at the end of the treatment period [69].
Post-marketing safety profile of the five-grass
pollen SLIT tablet
In Germany, post-marketing authorization safety studies
of pre- and co-seasonal treatment with a 300 IR five-
grass-pollen SLIT tablet have been carried out in chil-
dren and adults [39,59,60,70]. In one study, 354 study
centres across Germany enrolled 808 adults and 91 chil-
dren and adolescents with grass pollen-induced AR and/
or allergic conjunctivitis [39]. After a mean treatment
period of 191 days, 320 patients (35.6%) reported at least
one AE. The most common AEs were coded as oral
paresthesia (10.9% of events), oral pruritus (6.9%), throat
irritation (7.7%) and mouth oedema (5.3%). Eighty-five pa-
tients (9.5%) withdrew from treatment as a result of AEs.
In a second study, 207 centres enrolled 829 children
and adolescents aged between 5 and 17 years [70]. After
a mean treatment period of 190 days, 218 patients
(27.4%) reported at least one AE (mainly throat irritation
(n = 114), oral paresthesia (n = 49), oral pruritus (n = 39)
and mouth oedema (n = 37). The most serious AE
(Quincke’s oedema of the lips) occurred in a patient hav-
ing developed angioedema during a course of SCIT a
year earlier. Tolerability was rated as good or very good
by 84.7% of the patients, 87.0% of the parents and 89.7%
of the clinicians. Neither anaphylaxis nor adrenalin use
was recorded in these two studies [39,70]. Lastly, in a
2-year study based on grass pollen AIT renewal rates,
the persistence of treatment was significantly better in
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(p < 0.02) [55]. Hence, pre & co-seasonal (discontinuous)
treatment with a 300 IR five-grass-pollen SLIT tablet
shows good effectiveness and a good safety profile in
real-life clinical practice.
Comparisons of the efficacy and safety of pre-/co-
seasonal and perennial SLIT regimens
Few studies have performed head-to-head comparisons
of a pre- and co-seasonal regimen and a perennial
regimen. Obviously, single- or double-blind trials are dif-
ficult to perform if the durations of the compared treat-
ment regimens are clearly different (unless patients in
the pre-and-co-seasonal treated cohorts receive placebo
after the end of the season). A study by Sieber et al.
encompassed an independent patient data meta-analysis
of three open, prospective, observational trials of stan-
dardized Pooideae family or Betulaceae family pollen
SLIT preparations in a total of 1052 patients with
pollen-induced AR [61]. The objective was to indirectly
compare perennial treatments with co-seasonal treat-
ments and compare ultra-rush titration with standard
titration. The three studies respectively featured a peren-
nial regimen with classical titration, a co-seasonal regi-
men with ultra-rush titration and either a perennial or a
co-seasonal regimen. The most frequently used allergen
preparations contained Betulaceae pollen extracts (49.9%)
and Pooideae pollen extracts (41.6%). Overall, the various
treatment regimens were all associated with improvements
in symptom scores and medication scores (when compar-
ing the study period to a baseline period) and there were
no significant differences between the regimens. Sieber
et al. suggested that the equivalent effectiveness of co-
seasonal and perennial SLIT treatment might have an im-
pact on the yearly cost of treatment, although compliance
was not assessed [61].
Quercia performed a head-to-head study of a pre- and
co-seasonal regimen with a solely pre-seasonal regimen
[71]. The SLIT product was a tablet formulation of grass
pollen monomeric carbamylated allergoids. Three groups
of patients were studied. Group 1 took a 1,000 allergenic
unit (AU) tablet once a week continuously from November
2005 to July 2007 (i.e. through two grass pollen seasons).
Group 2 took a 1,000 AU tablet five times a week during
each 10-week pre-seasonal period solely. Both SLIT groups
showed a similar and significant improvement on a visual
analogue scale of symptom severity after the first and sec-
ond pollen seasons, relative to the baseline symptoms in
Groups 1 and 2 and also the symptoms of a third group of
patients (Group 3) taking symptomatic medications only.
The study had several limitations. Firstly, it used an open
design, although it is hard to conceive a fully double-blind,
controlled, randomized trial in which some patients (but
not others) are required to stop taking a treatment for acertain period of time. Secondly, the study subgroups were
small (n = 10, 11 and 11 in Groups 1 to 3, respectively).
Thirdly, Groups 1 and 2 did not receive the same dose of
allergen (on a per-week basis) in the presumably crucial
pre-seasonal period.
There are no head-to-head comparative studies of the
safety of a pre- and co-seasonal regimen vs. a year-
round regimen. However, in the pivotal European and
North America clinical trials of the grass pollen SLIT
tablets, the single-grass formulation and the five-grass
formulation did not appear to have radically different
safety profiles. Nelson et al. [37] commented that al-
though the majority of adult and paediatric patients
(60-80%) taken the single-grass tablet experienced
adverse events, the latter were generally local, mild-to-
moderate and transient. The most common local AEs
were oral pruritus (observed in 32-54% of patients on
active treatment in the various studies) and throat irri-
tation (in 9-37%). Systemic adverse events were rare
[37]. When summarizing the safety data for the five-grass
tablet, Didier et al. [39] used very similar language. Most
AEs during treatment were mild or moderate in severity,
with oral pruritus and throat irritation again being
among the most common (reported in >5% of patients)
[39]. No deaths or anaphylactic reactions were observed
in these trials.
In view of the published evidence, a pre-seasonal and
co-seasonal regimen appears to be sufficient for demon-
strating the efficacy and safety of SLIT formulations of a
300 IR birch pollen extract and a 300 IR five-grass
extract. On this basis, one can question whether year-
round SLIT regimens for pollen-induced AR have
added clinical or economic value. Indeed, a 75,000
SQ-T single-grass SLIT tablet registered with a year-
round regimen has been successfully applied in off-
label pre- and co-seasonal use [72]. In a multicentre,
prospective, open-label, observational study in France,
130 physicians treated a total of 628 patients for an
average of 5.5 months per year (with 4 months of pre-
seasonal treatment and then co-seasonal treatment)
for three successive seasons. Efficacy data were not re-
ported, since safety was the primary study criterion.
Treatment-related AEs were reported for respectively
46.2%, 14.4% and 1.8% of the patients during the first,
second and third years of the study. The compliance
rate was 71.8% in the first year, 86.8% in the second
year and 90.3% in the third year – again demonstrat-
ing the good compliance observed with pre- and
co-seasonal regimens [72]. Data from 934 patients
treated with the 75,000 SQ-T single-grass SLIT tablet
(registered for use with a year-round regimen) have
also been used to show that at least 2 months of
pre-seasonal treatment are required for clinical effi-
cacy [54].
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There are probable relationships between the mainten-
ance dose of allergen, clinical efficacy and the adminis-
tration regimen. It is now beyond doubt that AIT
involves a dose-response relationship. Of fifteen dose-
ranging studies reviewed by the European Academy of
Allergy and Clinical Immunology’s Task Force Report on
Dose-Response Relationship in Allergen-Specific Im-
munotherapy [73], twelve reported a dose-response rela-
tionship for clinical efficacy. In this respect, one can
consider the above-mentioned 300 IR five-grass-pollen
SLIT tablet and 75,000 SQ-T single-grass-pollen SLIT
tablet. According to the standardized unit for allergen
extracts required by the US Food and Drug Administra-
tion (the bioequivalent allergy unit, BAU, based on the
reaction to an intradermal test in highly allergic patients)
[74], the 300 IR five-grass-pollen SLIT tablet contains
9,000 BAU [75] and the 75,000 SQ-T single-grass-pollen
SLIT tablet contains 2,800 BAU [76]. According to the
respective manufacturers’ in-house assays, the major al-
lergen (Phl p 5) content is 25 μg for the 300 IR five-
grass-pollen SLIT tablet and 15 μg for the 75,000 SQ-T
single-grass-pollen SLIT tablet [64,77]. Although these
tablets differ in terms of BAUs and major allergen con-
tent (for optimal comparisons, these parameters should
be determined by the same laboratory in the same pa-
tients and using the same reagents [74,78]), the two
formulations appear to provide similar efficacy in the
first year of Phase III trials (as assessed by the effect
size for the rhinoconjunctivitis score, relative to pla-
cebo) [36-39]. When considering pre- and co-seasonal
regimens with grass-pollen tablets, only the 300 IR
five-grass formulation has proven sustained and post-
treatment efficacy in addition to single-season efficacy
[39]. Furthermore, a lower-dose (100 IR) five-grass-
pollen SLIT tablet was no more effective than placebo
in the pivotal, dose-ranging RCT [64].
The health economics of pre- and co-seasonal
regimens
Pre- and co-seasonal treatment regimens have economic
and compliance benefits relative to perennial regimens.
Firstly, a shorter duration of treatment of discontinuous
protocols implies that patients will receive less medication,
thus leading to a lower acquisition cost of medication. Two
studies evaluated the cost-effectiveness of pre- and co-
seasonal SLIT in grass pollen-induced AR [79,80].
Westerhout et al. undertook a cost-effectiveness ana-
lysis of 3 years of treatment with a pre- and co-seasonal
300 IR 5-grass pollen SLIT tablet (in addition to symp-
tomatic drug treatment (SDT)) over a time horizon of
9 years, compared with the following: (i) perennial SLIT
with a single grass tablet (in addition to SDT), (ii)perennial SCIT regimen (in addition to SDT), and (iii)
SDT alone (i.e. standard of care, SoC) for the treatment
of grass pollen-induced AR from the German health care
perspective [79]. Treatment efficacy was estimated based
on an indirect comparison of randomized controlled tri-
als (RCTs) with placebo (i.e. SoC) as a common com-
parator. Moreover, a meta-analysis of RCTs of the three
treatment regimens was conducted to determine the
effectiveness of each treatment relative to placebo (i.e.
SoC) for reducing AR symptom scores and improving
the number of symptom-free days. The results indicated
that relative to SDT alone, the incremental cost per
quality-adjusted life-year (QALY) gained with 300 IR 5-
grass pollen SLIT was €14,728, with incremental costs of
€1,356 and incremental QALYs of 0.092. The resulting
incremental cost-effectiveness ratio falls below com-
monly accepted thresholds in Europe. Meanwhile, rela-
tive to perennial single grass SLIT tablet or perennial
SCIT, estimated incremental cost savings with five-grass-
pollen SLIT tablet were respectively €1,142 and €54, and
the corresponding incremental QALYs were respectively
0.015 and 0.027. Hence, the results indicate that the
pre- and co-seasonal 5-grass pollen SLIT tablet is a cost-
effective treatment option (relative to perennial single
grass SLIT tablet, perennial SCIT and SDT alone) for
the treatment of grass pollen-induced allergic rhinitis in
Germany. However, extensive sensitivity analyses indicated
that the model’s outcomes may have been affected by un-
certainty surrounding treatment efficacy estimates [79].
In a recent economic study [80], a cost-minimization
analysis was conducted on the basis of a systematic review
of 20 DBPC trials in grass pollen-induced seasonal AR. The
following four treatment regimens from the Canadian
health care perspective: (i) pre- and co-seasonal treatment
with a 300 IR five-grass-pollen SLIT tablet, together with
SDT if required, and (ii) perennial SLIT with a single-grass
tablet, (iii) a perennial SCIT regimen, and (iv) a pre- and
co-seasonal SCIT regimen. The results indicated that the
pre- and co-seasonal 300 IR five-grass-pollen SLIT regimen
has at least non-inferior efficacy, similar safety and a lower
annual cost, when compared with perennial or seasonal
SCIT, and perennial SLIT with a single grass tablet [80].
During the first year of treatment, pre-and co-seasonal
administration of the 300 IR five-grass pollen SLIT
tablet plus SDT was associated with significant cost
savings relative to perennial SCIT (Can $2,471), sea-
sonal SCIT (Can $948), and perennial SLIT with a
single-grass tablet (Can $1,168) [80].
Conclusion
In pollen-induced AR, discontinuous SLIT regimens ap-
pear to be at least as effective and safe as perennial SLIT
regimens in terms of sustained efficacy over consecutive
pollen seasons, and even after the discontinuation of
Demoly et al. Clinical and Translational Allergy  (2015) 5:18 Page 8 of 10treatment. Head-to-head studies are required to estab-
lish whether discontinuous SLIT regimens are associated
with lower costs and/or better compliance or safety than
perennial SLIT regimens. When considering the pre-
and co-seasonal discontinuous regimen in particular, a
300 IR five-grass-pollen formulation is the only SLIT
tablet with a clinical development programme having
provided evidence of short-term, sustained and post-
treatment efficacy.
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